COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1

Chest. 2006 Jan;129(1):5-6. doi: 10.1378/chest.129.1.5.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
  • Animals
  • Carboxylic Acids / therapeutic use
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Cyclohexanecarboxylic Acids
  • Forced Expiratory Volume / drug effects
  • Humans
  • Inflammation / drug therapy
  • Inflammation / enzymology
  • Nitriles / therapeutic use
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / enzymology
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Treatment Outcome

Substances

  • Carboxylic Acids
  • Cyclohexanecarboxylic Acids
  • Nitriles
  • Phosphodiesterase Inhibitors
  • Cilomilast
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 4